Savara (SVRA)
NASDAQ:SVRA
Want to see SVRA full AI Analyst Report?
Top Page
Savara
(NASDAQ:SVRA)
Select Model
Select Model
Rating:44Neutral
Price Target:
$5.50
▼(-4.84% Downside)
Action:Reiterated
Date:06/09/26
The score is held down primarily by weak financial performance—no revenue, widening losses, and increasing cash burn that elevates funding/dilution risk. Technicals are broadly neutral and do not offset the fundamentals, while valuation is difficult to support with a negative P/E. Corporate actions increasing authorized shares further reinforce dilution risk.
Positive Factors
Manageable Leverage
Modest debt relative to equity gives Savara structural balance-sheet flexibility typical of early-stage biotechs. Lower leverage reduces near-term refinancing pressure, supporting continued clinical investment and preserving optionality for funding R&D over the next several quarters.
Negative Factors
High Cash Burn
Substantial and rising operating cash outflows materially shorten runway and increase the likelihood of near-term financing. Persistent negative free cash flow means the company will likely require external capital, which can pressure strategic choices and ownership dilution over time.
Read all positive and negative factors
Positive Factors
Negative Factors
Manageable Leverage
Modest debt relative to equity gives Savara structural balance-sheet flexibility typical of early-stage biotechs. Lower leverage reduces near-term refinancing pressure, supporting continued clinical investment and preserving optionality for funding R&D over the next several quarters.
Read all positive factors
Savara (SVRA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.21B
Dividend YieldN/A
Average Volume (3M)1.56M
Price to Earnings (P/E)―
Beta (1Y)1.24
Revenue GrowthN/A
EPS Growth-12.97%
CountryUS
Employees59
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.56
Shares Outstanding204,927,220
10 Day Avg. Volume1,844,887
30 Day Avg. Volume1,558,184
Financial Highlights & Ratios
PEG Ratio-1.09
Price to Book (P/B)6.60
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market Cap0.90
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.23K
Enterprise Value/Ebitda-8.46
Forecast
1Y Price Target
$11.17Price Target Upside93.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.54
Revenue Forecast (FY)$3.18M
Savara Business Overview & Revenue Model
Company Description
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimula...
How the Company Makes Money
null...
Savara Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -491.00K | -245.00K | -78.03M | -44.26M | -27.88M | -28.99M |
| EBITDA | -129.27M | -118.59M | -102.27M | -59.13M | -38.01M | -40.50M |
| Net Income | -129.48M | -118.84M | -95.88M | -54.70M | -38.15M | -43.01M |
Balance Sheet | ||||||
| Total Assets | 221.65M | 253.44M | 212.88M | 177.56M | 139.78M | 176.60M |
| Cash, Cash Equivalents and Short-Term Investments | 202.77M | 235.70M | 196.33M | 162.32M | 125.88M | 161.17M |
| Total Debt | 30.11M | 29.91M | 26.73M | 26.49M | 26.14M | 25.79M |
| Total Liabilities | 45.61M | 50.30M | 41.43M | 37.19M | 32.00M | 32.10M |
| Stockholders Equity | 176.04M | 203.13M | 171.45M | 140.37M | 107.78M | 144.50M |
Cash Flow | ||||||
| Free Cash Flow | -106.97M | -101.06M | -89.11M | -51.36M | -34.56M | -40.14M |
| Operating Cash Flow | -106.89M | -101.04M | -89.09M | -51.06M | -34.55M | -40.08M |
| Investing Cash Flow | -8.99M | -18.44M | -39.94M | -57.12M | 52.65M | -69.46M |
| Financing Cash Flow | 135.29M | 137.81M | 117.58M | 82.78M | 87.00K | 120.81M |
Savara Technical Analysis
Positive
5.78
Price Trends
5.25
Positive
5.38
Positive
5.14
Positive
Market Momentum
0.18
Negative
66.56
Neutral
85.89
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SVRA, the sentiment is Positive. The current price of 5.78 is above the 20-day moving average (MA) of 5.38, above the 50-day MA of 5.25, and above the 200-day MA of 5.14, indicating a bullish trend. The MACD of 0.18 indicates Negative momentum. The RSI at 66.56 is Neutral, neither overbought nor oversold. The STOCH value of 85.89 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SVRA.
Savara Risk Analysis
Savara disclosed 37 risk factors in its most recent earnings report. Savara reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Savara Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $715.85M | 1.93 | 147.03% | ― | 47.61% | 854.73% | |
60 Neutral | $1.84B | -74.29 | 442.91% | ― | 107.73% | 82.33% | |
60 Neutral | $1.77B | -9.67 | -35.89% | ― | ― | -63.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $994.89M | -5.64 | -45.95% | ― | ― | -3.83% | |
46 Neutral | $1.79B | -60.94 | 31.23% | ― | ― | ― | |
44 Neutral | $1.21B | -10.54 | -87.19% | ― | ― | -12.97% |
* Healthcare Sector Average
SVRA
Savara
5.90
3.62
158.77%
RIGL
Rigel
38.69
19.96
106.57%
ANAB
AnaptysBio
63.15
48.35
326.78%
OLMA
Olema Pharmaceuticals
11.39
7.13
167.37%
NBTX
Nanobiotix
35.99
31.26
660.89%
BCAX
Bicara Therapeutics Inc.
26.87
17.58
189.24%
Savara Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Savara Expands Share Capital and Updates Executive Leadership
Positive
Jun 8, 2026
On June 4, 2026, Savara’s stockholders approved an amendment to the 2024 Omnibus Incentive Plan, increasing the pool of shares available for equity awards by 18,900,000, and also doubled the company’s authorized common stock from 300,0...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.